**Dental Tribune** United Kingdom Edition · September 5-11, 2011

The ‘Challacombe’ Scale

A S Pharma discusses the severity and diagnosis of dry mouth

Treatment outcomes are increasingly recognised throughout UK health care as more important than other considerations such as meeting targets, inputs of expensive oral care and the acuteness of the rapid relative to the saliva flow and mucin density. The Scale has been proven over two years and provides a common reference point for use between clinicians, as well as indicating treatment options. While a high score is a clear indication that treatment is needed, the more radical option with a low score is not to intervene, which can be a demanding decision and often requires specialist knowledge. An additional benefit of the Challacombe Scale is that the patient’s progress can be monitored over time, measuring the efficacy of treatment or indeed introducing treatment in the event of deterioration.

Widespread lack of awareness among both clinicians and the general public has led to a frequent failure to diagnose and treat dry mouth, especially in the elderly. The misconception persists that age is a major contributory factor, despite the fact that over half (55 per cent) of octogenarians are experiencing this symptom.

Patients referred to the Guy’s Hospital Dry Mouth Clinic undergo tests for Sjögren’s syndrome, the most common autoimmune condition affecting glandular nerve impulses and lead to a 25 per cent reduction in the flow of saliva. When more than one drug is prescribed, the problem can be exacerbated by up to 75 per cent, and prescribing clinicians are not always fully aware of the combined effect on oral lubrication.

‘Evidence suggests that perhaps 20 per cent of the population suffers from a dry mouth, and numbers are growing’

Evidence suggests that perhaps 20 per cent of the population suffers from a dry mouth, and numbers are growing as more and more medications are prescribed which has the side effect of reducing saliva flow. There are more than 1,000 drugs in the BNF (British National Formulary), including those for treating high blood pressure, heart disease, anti- depressants, anti-histamines and many others, which impact gland secretions or affect glandular nerve impulses. The implication is that a significant population is suffering from xerostomia, or dry mouth, and numbers are growing. When more than one drug is prescribed, the problem can be exacerbated by up to 75 per cent, and prescribing clinicians are not always fully aware of the combined effect on oral lubrication.

Men and women, who are most commonly affected, may also suffer vaginal dryness. The Guy’s Hospital Dry Mouth Clinic team is participating in a major, multi-national study of Sjögren’s syndrome to widen understanding of the condition.

The traditional, and in many instances, persisting, role of an NHS dentist has been to prescribe ‘a drill and fill’ policy since the system of remuneration has discouraged a comprehensive oral examination. Patients are themselves more likely to consult their GP for non-tooth related symptoms, exacerbating the cost. Nevertheless, the dentist is usually better qualified to give a diagnosis, although the implication is that when a patient’s medical history needs to be stressed when prescription drugs are involved, to allow an understanding of the difference between ‘wetness’ and ‘lubrication’. This difference can be crucial when deciding whether to offer a saliva substitute.

The Challacombe Scale is not intended as a research tool but as a practical, clinical measure for dental professionals to assess the severity of dry mouth syndrome and to help them determine when treatment is required. The composition of saliva includes protein, and lubrication is also necessary throughout the length of the oesophagus to facilitate swallowing, and so wetting alone is not a solution in severe cases. Research carried out by the Guy’s Hospital Dry Mouth Clinic has confirmed that a 50 micron layer of mucin is necessary to maintain a smoothly functioning, healthy oral cavity.

By introducing a reliable, proven system of reference to this important but currently under-recognised area of oral health the Challacombe Scale offers practitioners an opportunity to discuss the problems of a dry mouth with patients who may have become resigned to the discomfort as a consequence of their medication, or in the mistaken belief that nothing can be done as they are simply getting older.

A S. Pharma is proud to be associated with this important work and Professor Challacombe’s pioneering scale.

For further information, please contact A S Pharma on telephone 08700 664 117 or email: info@aspharma.co.uk

About the author

Professor Stephen Challacombe of King’s College, London and Guy’s Hospital Dry Mouth Clinic, has developed the Challacombe Scale as a universally proven system of reference to assist in the diagnosis, management and treatment of symptoms of oral mucosal disease. The Scale is now accepted as a gold standard as it is the most commonly called.

It is the result of ten years’ work headed by Professor Challacombe who has co-authored over 350 peer reviewed papers on mucosal immune, immunological, dermatological and microbiological aspects of oral disease and is recognised as one of the leading experts in this specialist field.